Current evidence on GnRH agonist pretreatment before frozen embryo transfer and pregnancy outcomes in women with adenomyosis: a systematic review and meta-analysis

Adenomyosis is increasingly recognized as an important cause of infertility and reduced success rates in assisted reproductive technology (ART). Women with adenomyosis undergoing frozen embryo transfer (FET) have lower implantation and live birth rates compared to women without the disease. Gonadotropin-releasing hormone agonist (GnRH-a) pretreatment before FET has been proposed to improve reproductive outcomes by suppressing adenomyotic activity and enhancing endometrial receptivity; however, published studies have reported conflicting findings. The objective of this review was to evaluate the current evidence regarding the effectiveness of GnRH-a pretreatment before FET in women with adenomyosis. A systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and SCOPUS was performed up to November 9, 2024. Ten eligible studies, including randomized controlled trials and retrospective cohort studies, were identified. Outcomes included live birth, clinical pregnancy, biochemical pregnancy, and miscarriage rates. Although none of the pooled analyses reached statistical significance, GnRH-a pretreatment showed a consistent trend toward improved live birth and clinical pregnancy outcomes. The odds ratio for live birth was 1.47 per cycle and 1.23 per patient, favouring pretreatment. Clinical pregnancy rates also tended to improve, while biochemical pregnancy and miscarriage rates remained similar between groups. Current evidence suggests that GnRH-a pretreatment before FET may improve reproductive outcomes in women with adenomyosis, particularly live birth rates, although the quality of evidence remains limited by heterogeneity, retrospective study design, and inconsistent diagnostic criteria. These findings support the potential role of GnRH-a pretreatment in selected patients while highlighting the need for large, well-designed randomized controlled trials to establish clear clinical recommendations.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11527100/v1
Primary Topic
Endometriosis Research and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Current evidence on GnRH agonist pretreatment before frozen embryo transfer and pregnancy outcomes in women with adenomyosis: a systematic review and meta-analysis

Péter Hegyi, Boglárka Lilla Szentes, Miklós Sipos, Anett Rancz et al.
1 links
Research Square
Endometriosis Research and Treatment
preprint

Current evidence on GnRH agonist pretreatment before frozen embryo transfer and pregnancy outcomes in women with adenomyosis: a systematic review and meta-analysis

Péter Hegyi, Boglárka Lilla Szentes, Miklós Sipos, Anett Rancz, Andrea Harnos, Sándor Valent, Begüm Kepkep, Nándor Ács, Lőrinc Frivaldszky, Máté Szabolcs Botos
preprint en

Abstract

Adenomyosis is increasingly recognized as an important cause of infertility and reduced success rates in assisted reproductive technology (ART). Women with adenomyosis undergoing frozen embryo transfer (FET) have lower implantation and live birth rates compared to women without the disease. Gonadotropin-releasing hormone agonist (GnRH-a) pretreatment before FET has been proposed to improve reproductive outcomes by suppressing adenomyotic activity and enhancing endometrial receptivity; however, published studies have reported conflicting findings. The objective of this review was to evaluate the current evidence regarding the effectiveness of GnRH-a pretreatment before FET in women with adenomyosis. A systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and SCOPUS was performed up to November 9, 2024. Ten eligible studies, including randomized controlled trials and retrospective cohort studies, were identified. Outcomes included live birth, clinical pregnancy, biochemical pregnancy, and miscarriage rates. Although none of the pooled analyses reached statistical significance, GnRH-a pretreatment showed a consistent trend toward improved live birth and clinical pregnancy outcomes. The odds ratio for live birth was 1.47 per cycle and 1.23 per patient, favouring pretreatment. Clinical pregnancy rates also tended to improve, while biochemical pregnancy and miscarriage rates remained similar between groups. Current evidence suggests that GnRH-a pretreatment before FET may improve reproductive outcomes in women with adenomyosis, particularly live birth rates, although the quality of evidence remains limited by heterogeneity, retrospective study design, and inconsistent diagnostic criteria. These findings support the potential role of GnRH-a pretreatment in selected patients while highlighting the need for large, well-designed randomized controlled trials to establish clear clinical recommendations.

Research Square
Semmelweis University (HU)
Semmelweis Egyetem
Good health and well-being
Endometriosis Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon